Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology Inc (CRDF) is a clinical-stage biotech company advancing novel therapies targeting cancers with high unmet need through its focus on PLK1 inhibition. This page provides investors and researchers with timely updates on clinical developments, strategic initiatives, and scientific breakthroughs driving the company's precision oncology pipeline.
Access the latest CRDF news including trial updates for RAS-mutated mCRC and other challenging cancers, partnership announcements, and regulatory milestones. Our curated collection features press releases on onvansertib developments, peer-reviewed data highlights, and management commentary to inform your analysis of this innovative oncology player.
Key content categories include Phase 2 trial progress updates, scientific conference presentations, and operational developments shaping Cardiff's therapeutic pipeline. Bookmark this page for streamlined tracking of CRDF's efforts to transform cancer treatment through mechanism-driven approaches.
Cardiff Oncology announced the publication of Phase 2 trial data in the Journal of Clinical Oncology, evaluating onvansertib combined with FOLFIRI and bevacizumab for second-line treatment of KRAS mutant metastatic colorectal cancer (mCRC). The study showed significant results, particularly in bevacizumab-naïve patients, demonstrating a 77% objective response rate compared to 10% in bevacizumab-exposed patients. The treatment combination showed a median progression-free survival of 14.9 months in bevacizumab-naïve patients versus 6.6 months in bevacizumab-exposed patients. Based on these findings, the company has initiated CRDF-004, a Phase 2 randomized trial for first-line treatment, with initial data expected in H2 2024.
Cardiff Oncology (Nasdaq: CRDF) reported Q2 2024 results and provided a business update. Key highlights include:
1. Initial readout from first-line RAS-mut. mCRC randomized CRDF-004 trial expected in 2H 2024.
2. Preclinical data shows onvansertib's potential to overcome PARP inhibitor resistance in ovarian cancer.
3. Five abstracts presented at AACR support onvansertib's development across multiple tumor types.
4. Cash and equivalents of $60 million as of June 30, 2024, with projected runway through Q3 2025.
5. Q2 2024 operating expenses increased to $12.7 million from $12.3 million in Q2 2023.
6. Net cash used in operating activities for Q2 2024 was $9.2 million, up from $7.1 million in Q2 2023.
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology company focusing on PLK1 inhibition for cancer therapies, has announced its plan to release second quarter 2024 financial results on Thursday, August 8 after market close. The company will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day to discuss the results and provide a business update. Interested parties can access the webcast through the 'Investors' section of Cardiff Oncology's website. A replay of the call will be available in the investor relations section following the event.
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology firm specializing in PLK1 inhibition to develop cancer therapies, will present at the Jefferies Healthcare Conference in New York on June 5-6, 2024. CEO Mark Erlander will present on June 5, 2024, from 8:30 to 8:55 AM ET in Track 8. The company will also hold 1x1 meetings with investors. Interested parties can access live webcasts and replays of the presentations via Cardiff Oncology's website.
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology company, will present at two investor conferences in May 2024. The first, H.C. Wainwright 2nd Annual BioConnect Investor Conference, will be held at the Nasdaq Headquarters in New York City on May 20, 2024, at 2:30 PM ET. The second, Cowen 5th Annual Oncology Innovation Summit, will be a virtual event on May 29, 2024, at 1:30 PM ET. CEO Mark Erlander will represent Cardiff Oncology in fireside chats at both events. Interested parties can access live webcasts via Cardiff Oncology's website, with replays available post-event.
Cardiff Oncology, Inc. (Nasdaq: CRDF) reported Q1 2024 results and provided a business update, highlighting strong efficacy in RAS-mutated mCRC and onvansertib's potential across various cancers. The company has $67M in cash, projecting runway into Q3 2025. Key milestones include upcoming data readouts, trials, and preclinical data presentations. Financially, total operating expenses decreased, with funds expected to last into Q3 2025.